136 related articles for article (PubMed ID: 28322226)
1. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SGT; Liu K; Iyer SP; Bearss D; Bhalla KN
Leukemia; 2017 Jul; 31(7):1658. PubMed ID: 28322226
[TBL] [Abstract][Full Text] [Related]
2. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
[TBL] [Abstract][Full Text] [Related]
3. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).
Li Z; Ding L; Li Z; Wang Z; Suo F; Shen D; Zhao T; Sun X; Wang J; Liu Y; Ma L; Zhao B; Geng P; Yu B; Zheng Y; Liu H
Acta Pharm Sin B; 2019 Jul; 9(4):794-808. PubMed ID: 31384539
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of neuronal Lysine-Specific Demethylase 1LSD1/KDM1A impairs transcriptional repression by regulating interaction with CoREST and histone deacetylases HDAC1/2.
Toffolo E; Rusconi F; Paganini L; Tortorici M; Pilotto S; Heise C; Verpelli C; Tedeschi G; Maffioli E; Sala C; Mattevi A; Battaglioli E
J Neurochem; 2014 Mar; 128(5):603-16. PubMed ID: 24111946
[TBL] [Abstract][Full Text] [Related]
5. Oncogene LSD1 is epigenetically suppressed by miR-137 overexpression in human non-small cell lung cancer.
Zhang X; Zhang X; Yu B; Hu R; Hao L
Biochimie; 2017 Jun; 137():12-19. PubMed ID: 28223039
[TBL] [Abstract][Full Text] [Related]
6. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
[TBL] [Abstract][Full Text] [Related]
7. Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML.
Lokken AA; Zeleznik-Le NJ
Cancer Cell; 2012 Apr; 21(4):451-3. PubMed ID: 22516254
[TBL] [Abstract][Full Text] [Related]
8. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J
Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306
[TBL] [Abstract][Full Text] [Related]
9. Somatic deletion of
Ramírez-Ramírez R; Gutiérrez-Angulo M; Peregrina-Sandoval J; Moreno-Ortiz JM; Franco-Topete RA; Cerda-Camacho FJ; Ayala-Madrigal ML
J Clin Pathol; 2020 Feb; 73(2):107-111. PubMed ID: 31471467
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.
Schenk T; Chen WC; Göllner S; Howell L; Jin L; Hebestreit K; Klein HU; Popescu AC; Burnett A; Mills K; Casero RA; Marton L; Woster P; Minden MD; Dugas M; Wang JC; Dick JE; Müller-Tidow C; Petrie K; Zelent A
Nat Med; 2012 Mar; 18(4):605-11. PubMed ID: 22406747
[TBL] [Abstract][Full Text] [Related]
11. Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication.
Ishikawa Y; Nakayama K; Morimoto M; Mizutani A; Nakayama A; Toyoshima K; Hayashi A; Takagi S; Dairiki R; Miyashita H; Matsumoto S; Gamo K; Nomura T; Nakamura K
Oncogenesis; 2017 Sep; 6(9):e377. PubMed ID: 28892104
[TBL] [Abstract][Full Text] [Related]
12. Histone methyl-transferases and demethylases in the autophagy regulatory network: the emerging role of KDM1A/LSD1 demethylase.
Ambrosio S; Ballabio A; Majello B
Autophagy; 2019 Feb; 15(2):187-196. PubMed ID: 30208749
[TBL] [Abstract][Full Text] [Related]
13. Capsaicin: A "hot" KDM1A/LSD1 inhibitor from peppers.
Jia G; Cang S; Ma P; Song Z
Bioorg Chem; 2020 Oct; 103():104161. PubMed ID: 32889380
[TBL] [Abstract][Full Text] [Related]
14. LSD1 (KDM1A)-independent effects of the LSD1 inhibitor SP2509 in cancer cells.
Sonnemann J; Zimmermann M; Marx C; Ebert F; Becker S; Lauterjung ML; Beck JF
Br J Haematol; 2018 Nov; 183(3):494-497. PubMed ID: 29205263
[No Abstract] [Full Text] [Related]
15. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Is a Novel Target Gene of c-Myc.
Nagasaka M; Tsuzuki K; Ozeki Y; Tokugawa M; Ohoka N; Inoue Y; Hayashi H
Biol Pharm Bull; 2019; 42(3):481-488. PubMed ID: 30828079
[TBL] [Abstract][Full Text] [Related]
16. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells.
Fang J; Ying H; Mao T; Fang Y; Lu Y; Wang H; Zang I; Wang Z; Lin Y; Zhao M; Luo X; Wang Z; Zhang Y; Zhang C; Xiao W; Wang Y; Tan W; Chen Z; Lu C; Atadja P; Li E; Zhao K; Liu J; Gu J
Oncotarget; 2017 Oct; 8(49):85085-85101. PubMed ID: 29156705
[TBL] [Abstract][Full Text] [Related]
18. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
[TBL] [Abstract][Full Text] [Related]
19. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract][Full Text] [Related]
20. Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity Relationship.
Vianello P; Sartori L; Amigoni F; Cappa A; Fagá G; Fattori R; Legnaghi E; Ciossani G; Mattevi A; Meroni G; Moretti L; Cecatiello V; Pasqualato S; Romussi A; Thaler F; Trifiró P; Villa M; Botrugno OA; Dessanti P; Minucci S; Vultaggio S; Zagarrí E; Varasi M; Mercurio C
J Med Chem; 2017 Mar; 60(5):1693-1715. PubMed ID: 28186757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
